Nonalcoholic steatohepatitis

(NASH)

NASH studies are challenging as patients may not view themselves as sick and thus will not want to participate in treatment trials. Since they do not feel sick, study drug adherence may be challenged, leading to noncompliance, and increased dropout rates.

The ClinOne platform is designed to significantly improve patient study experience, reduce risk, assist with travel challenges, and provide cost saving measures through technology.

Improve Enrollment Within a Highly Competitive Indication

MD Referral | Traditional recruitment methods typically underperform. ClinOne enhances your efforts by communicating directly with global specialists and physicians in our proprietary network who are located nearby your clinical sites and may have eligible patients to refer. ClinOne’s technology expands to patient advocacy groups and associations to further improve your trial’s visibility within the NASH community.

Enable Remote Consent Before Patients Travel to Research Sites

eConsent | NASH studies often require remote consents before traveling to research sites. ClinOne eConsent eliminates the risk of consents, sub-study consents and reconsents by providing streamlined consent technology and comprehensive audit log. ClinOne eConsent provides on-site and remote video consent capabilities to ensure timely consent opportunities and reduce unnecessary site visits. eConsent ensures patients and families understand the benefits and risks of the study so they can make an informed participation decision, which in turn supports increased compliance and retention, while minimizing or eliminating consent-related audit findings.

Help NASH Patients and Families Manage Their Study Experience

  • Event Manager provides a detailed schedule of events and visit guide to properly prepare the patients for each visit and reduce missed visit rate by 50%.
  • Telemedicine visits allow study teams to communicate directly with their patients and families in real time to assess symptoms, issues, and progress while reducing the time and effort of costly onsite visits. At the same time, Principal Investigators and research staff can assess the patient virtually and make treatment decisions regarding the study medications and effects.
  • Transportation is included through a seamless integration with Uber Health, including wheelchair assessable transportation.

Improve Safety and Eliminate Unnecessary Site Visits

Connected Devices | Integrating objective and biometric data from convenient wearable sensors can improve safety monitoring (e.g. SPO2, fall detection, blood pressure) and provide real-world insight into activity, sleep, and other digital endpoints. Increasingly, regulatory authorities are reviewing these data to make labelling decisions and assess the true impact of your investigational treatment on patients. Ensure you have the complete picture of patient response with connected devices on the ClinOne platform.

Improve Dosing for Self-administered Medication

Dosing Manager | Many NASH trials require patients to self-administer medication. ClinOne’s dosing compliance module raises dosing compliance to industry leading compliance rates of 92% dosing compliance at 12-months on study. Patients can complete their dosing diary from personal devices, further increasing convenience and compliance.